205 related articles for article (PubMed ID: 24022228)
21. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
22. Conversion from epoetin and darbepoetin to C.E.R.A. in non-dialysis CKD patients: a multicenter Italian prospective study in nephrology practice.
Minutolo R; Conte G; Cozzolino M; Polito P; Manno C; Di Iorio BR; Santoro D; Di Luca M; Nappi F; Feriozzi S; Sasso FC; De Nicola L
Blood Purif; 2013; 36(2):69-77. PubMed ID: 23989045
[TBL] [Abstract][Full Text] [Related]
23. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
24. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
[TBL] [Abstract][Full Text] [Related]
25. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
[TBL] [Abstract][Full Text] [Related]
26. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta.
Bock HA; Hirt-Minkowski P; Brünisholz M; Keusch G; Rey S; von Albertini B;
Nephrol Dial Transplant; 2008 Jan; 23(1):301-8. PubMed ID: 17890745
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
28. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.
Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
Ther Apher Dial; 2014 Oct; 18(5):414-20. PubMed ID: 24456373
[TBL] [Abstract][Full Text] [Related]
30. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
31. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
32. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
33. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].
Ito C; Akimoto T; Morishita Y; Yamamoto H; Ogura M; Yamazaki T; Miki A; Homma S; Kusano E; Asano Y; Nagata D
Nihon Jinzo Gakkai Shi; 2015; 57(7):1233-40. PubMed ID: 26665615
[TBL] [Abstract][Full Text] [Related]
35. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
36. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
[TBL] [Abstract][Full Text] [Related]
37. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
38. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.
Oh J; Joo KW; Chin HJ; Chae DW; Kim SG; Kim SJ; Chung W; Kim S; Huh W; Oh HY; Choi BS; Yang CW; Kim S
J Korean Med Sci; 2014 Jan; 29(1):76-83. PubMed ID: 24431909
[TBL] [Abstract][Full Text] [Related]
39. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.
Locatelli F; Villa G; de Francisco AL; Albertazzi A; Adrogue HJ; Dougherty FC; Beyer U;
Curr Med Res Opin; 2007 May; 23(5):969-79. PubMed ID: 17519064
[TBL] [Abstract][Full Text] [Related]
40. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.
Choy BY; Lam MF; Yip T; Tang HL; Wong PN; Chow CC; Yap DY; Chan TM
Nephrology (Carlton); 2013 Aug; 18(8):533-8. PubMed ID: 23714233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
